Works matching IS 21534888 AND DT 2018 AND VI 9 AND IP 1
Results: 33
Encouraging Efficacy and Safety with Enasidenib or Ivosidenib plus Azacitidine in Patients with Newly Diagnosed AML.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 27
- Publication type:
- Article
Safety and Tolerability of Midostaurin from Expanded Treatment Protocol in Patients with FLT3 Mutation-Positive, Newly Diagnosed AML.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 27
- Publication type:
- Article
Enasidenib Monotherapy Is Well-Tolerated and Active in Older Patients with Untreated mIDH2 AML.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 26
- Publication type:
- Article
Nivolumab plus Azacitidine Shows Encouraging Activity in R/R AML or as Frontline Therapy in Elderly Patients with AML.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 26
- Publication type:
- Article
PET-Directed Approach Can Guide Radiation Therapy in Diffuse Large B-Cell Lymphoma.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 25
- By:
- Publication type:
- Article
Brentuximab Vedotin plus Nivolumab Yields High Complete Responses in Relapsed or Refractory Hodgkin Lymphoma.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 24
- By:
- Publication type:
- Article
High Response Rate with 3-Drug Combination for Untreated Follicular Lymphoma.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 24
- By:
- Publication type:
- Article
A New Combination as First-Line Regimen in Advanced Hodgkin Lymphoma?
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 23
- By:
- Publication type:
- Article
Daratumumab Therapy for Smoldering Myeloma Extends Progression-Free Survival.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 22
- By:
- Publication type:
- Article
Lenalidomide plus Elotuzumab Maintenance Regimen Improves Responses in Multiple Myeloma.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 22
- By:
- Publication type:
- Article
Venetoclax plus Rituximab New Chemotherapy-Free Option for Chronic Lymphocytic Leukemia.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 21
- Publication type:
- Article
New BTK Inhibitor Leads to Durable Responses in Relapsed or Refractory Chronic Lymphocytic Leukemia.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 21
- By:
- Publication type:
- Article
Recent FDA Approvals for ALL a "Watershed" Moment.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 19
- Publication type:
- Article
Ibrutinib plus Venetoclax Combo Elicits Impressive Responses in Relapsed Chronic Lymphocytic Leukemia.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 19
- By:
- Publication type:
- Article
Profound Symptom Burden of Myeloproliferative Neoplasms Highlighted in New Studies.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 18
- By:
- Publication type:
- Article
Median 3.5-Year Follow-Up of Ibrutinib Treatment in Patients with...
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 17
- Publication type:
- Article
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 17
- Publication type:
- Article
Adverse Events, Resource Use, and Economic Burden in Patients with Mantle-Cell Lymphoma in the United States.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 17
- Publication type:
- Article
Median 3.5-Year Follow-Up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle-Cell Lymphoma: A Pooled Analysis.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 16
- Publication type:
- Article
Preliminary Results of Prophylactic Tocilizumab After Axicabtagene Ciloleucel (axi-cel; KTE-C19) Treatment for Patients with Relapsed/Refractory, Aggressive NHL.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 16
- Publication type:
- Article
Phase 2 Study of Brentuximab Vedotin plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 16
- Publication type:
- Article
Acute Myeloid Leukemia Treatment Episodes Linked to Significant Economic Burden.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 15
- By:
- Publication type:
- Article
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 15
- By:
- Publication type:
- Article
Which Combination Immunotherapies to Use, and When? High Response Rates, but Serious Toxicity Remains a Concern.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 14
- By:
- Publication type:
- Article
Novel TKI Leads to Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 12
- By:
- Publication type:
- Article
CAR T-Cell Therapy Shows "Impressive" Results in Multiple Myeloma.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 12
- By:
- Publication type:
- Article
Quizartinib Combinations Show High Activity in Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 11
- By:
- Publication type:
- Article
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 11
- By:
- Publication type:
- Article
First-in-Class Sotatercept Improves Hemoglobin Levels in Anemic Patients with Myelofibrosis.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 10
- By:
- Publication type:
- Article
Mogamulizumab, Anti-CCR4 Antibody, Improves Survival in Patients with Advanced Cutaneous T-Cell Lymphoma.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 1
- By:
- Publication type:
- Article
CAR T-Cell Therapy Makes Significant Inroads in Lymphoma: Kymriah and Yescarta Show Durable Remissions.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 1
- By:
- Publication type:
- Article
ASH Recaps "Phenomenal" Year for Acute Myeloid Leukemia Drug Approvals.
- Published in:
- Value-Based Cancer Care, 2018, v. 9, n. 1, p. 1
- By:
- Publication type:
- Article
Precision Medicine and Immunotherapy Highlighted at ASH 2017.
- Published in:
- 2018
- By:
- Publication type:
- Proceeding